Observations placeholder
Xtandi
Identifier
024188
Type of Spiritual Experience
Number of hallucinations: 57
Background
A description of the experience
Enzalutamide (brand name Xtandi) is a synthetic non-steroidal antiandrogen (NSAA) which was developed by the pharmaceutical company Medivation for the treatment of metastatic, castration-resistant prostate cancer. Medivation has reported up to an 89% decrease in serum prostate specific antigen (PSA) levels after a month of taking the drug. Research suggests that enzalutamide may also be effective in the treatment of certain types of breast cancer. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of castration-resistant prostate cancer.
Most common Xtandi side effects from eHealthme
- Death - (2,504 reports)
- Fatigue - (2,351 reports)
- Malignant neoplasm progression - (1,543 reports)
- Drug ineffective - (1,242 reports)
- Weakness - (1,012 reports)
- Nausea - (885 reports)
- Prostatic specific antigen increased - (877 reports)
- Appetite - decreased - (850 reports)
- Dizziness - (702 reports)
- Diarrhea - (670 reports)